A federal jury in Delaware put US biotech major Amgen (Nasdaq: AMGN) on the hook Thursday for at least $271.2 million in ...

Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

and Otezla ® (apremilast) to convince pharmacy benefit managers (PBMs) to select Repatha ® (evolocumab) as the exclusive PCSK9 category product over Praluent ® (alirocumab). The jury found that ...

and Otezla (apremilast) to convince pharmacy benefit managers (PBMs) to select Repatha (evolocumab) as the exclusive PCSK9 category product over Praluent (alirocumab). The jury found that Amgen ...

The Psoriatic Arthritis Long-t erm Assessment of Clinical Efficacy (PALACE) trial programme found Otezla to be superior to placebo but "compared with TNF-alpha inhibitors, apremilast was the ...

aiming to mount a challenge to Amgen's $2.3 billion oral psoriasis therapy Otezla (apremilast). BMS has previously said it reckons Sotyktu could become a $4 billion seller at its peak, fuelled by ...

from competing in the market Jury awarded Regeneron $135.6 million dollars of compensatory damages and $271.2 million dollars in punitive damages Enbrel and Otezla are therapeutically different ...

from competing in the market Jury awarded Regeneron $135.6 million dollars of compensatory damages and $271.2 million dollars in punitive damages Enbrel and Otezla are therapeutically different ...